Literature DB >> 17082611

Reversing tumor immune suppression with intratumoral IL-12: activation of tumor-associated T effector/memory cells, induction of T suppressor apoptosis, and infiltration of CD8+ T effectors.

Mehmet O Kilinc1, Karanvir S Aulakh, Raji E Nair, Stacy A Jones, Pascale Alard, Michele M Kosiewicz, Nejat K Egilmez.   

Abstract

A single intratumoral injection of IL-12 and GM-CSF-loaded slow-release microspheres induces T cell-dependent eradication of established primary and metastatic tumors in a murine lung tumor model. To determine how the delivery of cytokines directly to the microenvironment of a tumor nodule induces local and systemic antitumor T cell activity, we characterized therapy-induced phenotypic and functional changes in tumor-infiltrating T cell populations. Analysis of pretherapy tumors demonstrated that advanced primary tumors were infiltrated by CD4+ and CD8+ T cells with an effector/memory phenotype and CD4+CD25+Foxp3+ T suppressor cells. Tumor-associated effector memory CD8+ T cells displayed impaired cytotoxic function, whereas CD4+CD25+Foxp3+ cells effectively inhibited T cell proliferation demonstrating functional integrity. IL-12/GM-CSF treatment promoted a rapid up-regulation of CD43 and CD69 on CD8+ effector/memory T cells, augmented their ability to produce IFN-gamma, and restored granzyme B expression. Importantly, treatment also induced a concomitant and progressive loss of T suppressors from the tumor. Further analysis established that activation of pre-existing effector memory T cells was short-lived and that both the effector/memory and the suppressor T cells became apoptotic within 4 days of treatment. Apoptotic death of pre-existing effector/memory and suppressor T cells was followed by infiltration of the tumor with activated, nonapoptotic CD8+ effector T lymphocytes on day 7 posttherapy. Both CD8+ T cell activation and T suppressor cell purge were mediated primarily by IL-12 and required IFN-gamma. This study provides important insight into how local IL-12 therapy alters the immunosuppressive tumor milieu to one that is immunologically active, ultimately resulting in tumor regression.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17082611     DOI: 10.4049/jimmunol.177.10.6962

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  56 in total

Review 1.  Exercise training and immune crosstalk in breast cancer microenvironment: exploring the paradigms of exercise-induced immune modulation and exercise-induced myokines.

Authors:  Jorming Goh; Negin Niksirat; Kristin L Campbell
Journal:  Am J Transl Res       Date:  2014-10-11       Impact factor: 4.060

2.  Dichotomous effects of IFN-γ on dendritic cell function determine the extent of IL-12-driven antitumor T cell immunity.

Authors:  Jamie L Harden; Tao Gu; Mehmet O Kilinc; Rachael B Rowswell-Turner; Lauren P Virtuoso; Nejat K Egilmez
Journal:  J Immunol       Date:  2011-06-01       Impact factor: 5.422

Review 3.  IFN-γ: A cytokine at the right time, is in the right place.

Authors:  J Daniel Burke; Howard A Young
Journal:  Semin Immunol       Date:  2019-06-17       Impact factor: 11.130

4.  Interleukin 12 stimulates IFN-gamma-mediated inhibition of tumor-induced regulatory T-cell proliferation and enhances tumor clearance.

Authors:  Xuefang Cao; Karen Leonard; Lynne I Collins; Sheng F Cai; Joshua C Mayer; Jacqueline E Payton; Michael J Walter; David Piwnica-Worms; Robert D Schreiber; Timothy J Ley
Journal:  Cancer Res       Date:  2009-10-20       Impact factor: 12.701

5.  The role of interleukin-12 on modulating myeloid-derived suppressor cells, increasing overall survival and reducing metastasis.

Authors:  Catherine E Steding; Sung-tse Wu; Yanping Zhang; Meei-Huey Jeng; Bennett D Elzey; Chinghai Kao
Journal:  Immunology       Date:  2011-04-01       Impact factor: 7.397

6.  Fusions of dendritic cells with breast carcinoma stimulate the expansion of regulatory T cells while concomitant exposure to IL-12, CpG oligodeoxynucleotides, and anti-CD3/CD28 promotes the expansion of activated tumor reactive cells.

Authors:  Baldev Vasir; Zekui Wu; Keith Crawford; Jacalyn Rosenblatt; Corrine Zarwan; Adam Bissonnette; Donald Kufe; David Avigan
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

7.  Defective MHC class II presentation by dendritic cells limits CD4 T cell help for antitumor CD8 T cell responses.

Authors:  Michael Y Gerner; Kerry A Casey; Matthew F Mescher
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

8.  Role of chitosan co-formulation in enhancing interleukin-12 delivery and antitumor activity.

Authors:  Lirong Yang; David A Zaharoff
Journal:  Biomaterials       Date:  2013-02-27       Impact factor: 12.479

Review 9.  Harnessing the immune system to improve cancer therapy.

Authors:  Nikos E Papaioannou; Ourania V Beniata; Panagiotis Vitsos; Ourania Tsitsilonis; Pinelopi Samara
Journal:  Ann Transl Med       Date:  2016-07

10.  Inhibition of lysosomal enzyme activities by proton pump inhibitors.

Authors:  Wensheng Liu; Susan S Baker; Jonathan Trinidad; Alma L Burlingame; Robert D Baker; John G Forte; Lauren P Virtuoso; Nejat K Egilmez; Lixin Zhu
Journal:  J Gastroenterol       Date:  2013-03-12       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.